-
Something wrong with this record ?
Mitochondrial nucleoid clusters protect newly synthesized mtDNA during Doxorubicin- and Ethidium Bromide-induced mitochondrial stress
L. Alán, T. Špaček, D. Pajuelo Reguera, M. Jabůrek, P. Ježek,
Language English Country United States
Document type Journal Article
- MeSH
- Hep G2 Cells MeSH
- DNA-Binding Proteins metabolism MeSH
- Doxorubicin MeSH
- Ethidium MeSH
- GTP Phosphohydrolases metabolism MeSH
- Mitochondria, Liver metabolism MeSH
- Humans MeSH
- DNA, Mitochondrial metabolism MeSH
- Mitochondrial Proteins metabolism MeSH
- Tumor Suppressor Protein p53 metabolism MeSH
- DNA Damage MeSH
- Microtubule-Associated Proteins metabolism MeSH
- Transcription Factors metabolism MeSH
- Mitochondrial Membrane Transport Proteins metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Mitochondrial DNA (mtDNA) is compacted in ribonucleoprotein complexes called nucleoids, which can divide or move within the mitochondrial network. Mitochondrial nucleoids are able to aggregate into clusters upon reaction with intercalators such as the mtDNA depletion agent Ethidium Bromide (EB) or anticancer drug Doxorobicin (DXR). However, the exact mechanism of nucleoid clusters formation remains unknown. Resolving these processes may help to elucidate the mechanisms of DXR-induced cardiotoxicity. Therefore, we addressed the role of two key nucleoid proteins; mitochondrial transcription factor A (TFAM) and mitochondrial single-stranded binding protein (mtSSB); in the formation of mitochondrial nucleoid clusters during the action of intercalators. We found that both intercalators cause numerous aberrations due to perturbing their native status. By blocking mtDNA replication, both agents also prevented mtDNA association with TFAM, consequently causing nucleoid aggregation into large nucleoid clusters enriched with TFAM, co-existing with the normal nucleoid population. In the later stages of intercalation (>48h), TFAM levels were reduced to 25%. In contrast, mtSSB was released from mtDNA and freely distributed within the mitochondrial network. Nucleoid clusters mostly contained nucleoids with newly replicated mtDNA, however the nucleoid population which was not in replication mode remained outside the clusters. Moreover, the nucleoid clusters were enriched with p53, an anti-oncogenic gatekeeper. We suggest that mitochondrial nucleoid clustering is a mechanism for protecting nucleoids with newly replicated DNA against intercalators mediating genotoxic stress. These results provide new insight into the common mitochondrial response to mtDNA stress and can be implied also on DXR-induced mitochondrial cytotoxicity.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024050
- 003
- CZ-PrNML
- 005
- 20170830103403.0
- 007
- ta
- 008
- 170720s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.taap.2016.04.011 $2 doi
- 035 __
- $a (PubMed)27102948
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Alán, Lukáš $u Dept. 75, Institute of Physiology, Academy of Sciences of the Czech Republic v.v.i, Czech Republic. Electronic address: lukas.alan@fgu.cas.cz. $7 gn_A_00003279
- 245 10
- $a Mitochondrial nucleoid clusters protect newly synthesized mtDNA during Doxorubicin- and Ethidium Bromide-induced mitochondrial stress / $c L. Alán, T. Špaček, D. Pajuelo Reguera, M. Jabůrek, P. Ježek,
- 520 9_
- $a Mitochondrial DNA (mtDNA) is compacted in ribonucleoprotein complexes called nucleoids, which can divide or move within the mitochondrial network. Mitochondrial nucleoids are able to aggregate into clusters upon reaction with intercalators such as the mtDNA depletion agent Ethidium Bromide (EB) or anticancer drug Doxorobicin (DXR). However, the exact mechanism of nucleoid clusters formation remains unknown. Resolving these processes may help to elucidate the mechanisms of DXR-induced cardiotoxicity. Therefore, we addressed the role of two key nucleoid proteins; mitochondrial transcription factor A (TFAM) and mitochondrial single-stranded binding protein (mtSSB); in the formation of mitochondrial nucleoid clusters during the action of intercalators. We found that both intercalators cause numerous aberrations due to perturbing their native status. By blocking mtDNA replication, both agents also prevented mtDNA association with TFAM, consequently causing nucleoid aggregation into large nucleoid clusters enriched with TFAM, co-existing with the normal nucleoid population. In the later stages of intercalation (>48h), TFAM levels were reduced to 25%. In contrast, mtSSB was released from mtDNA and freely distributed within the mitochondrial network. Nucleoid clusters mostly contained nucleoids with newly replicated mtDNA, however the nucleoid population which was not in replication mode remained outside the clusters. Moreover, the nucleoid clusters were enriched with p53, an anti-oncogenic gatekeeper. We suggest that mitochondrial nucleoid clustering is a mechanism for protecting nucleoids with newly replicated DNA against intercalators mediating genotoxic stress. These results provide new insight into the common mitochondrial response to mtDNA stress and can be implied also on DXR-induced mitochondrial cytotoxicity.
- 650 _2
- $a poškození DNA $7 D004249
- 650 _2
- $a mitochondriální DNA $x metabolismus $7 D004272
- 650 _2
- $a DNA vazebné proteiny $x metabolismus $7 D004268
- 650 _2
- $a doxorubicin $7 D004317
- 650 _2
- $a ethidium $7 D004996
- 650 _2
- $a GTP-fosfohydrolasy $x metabolismus $7 D020558
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a proteiny asociované s mikrotubuly $x metabolismus $7 D008869
- 650 _2
- $a jaterní mitochondrie $x metabolismus $7 D008930
- 650 _2
- $a transportní proteiny mitochondriální membrány $x metabolismus $7 D033681
- 650 _2
- $a mitochondriální proteiny $x metabolismus $7 D024101
- 650 _2
- $a transkripční faktory $x metabolismus $7 D014157
- 650 _2
- $a nádorový supresorový protein p53 $x metabolismus $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Špaček, Tomáš $u Dept. 75, Institute of Physiology, Academy of Sciences of the Czech Republic v.v.i, Czech Republic.
- 700 1_
- $a Pajuelo Reguera, David $u Dept. 75, Institute of Physiology, Academy of Sciences of the Czech Republic v.v.i, Czech Republic.
- 700 1_
- $a Jabůrek, Martin $u Dept. 75, Institute of Physiology, Academy of Sciences of the Czech Republic v.v.i, Czech Republic.
- 700 1_
- $a Ježek, Petr $u Dept. 75, Institute of Physiology, Academy of Sciences of the Czech Republic v.v.i, Czech Republic.
- 773 0_
- $w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 302, č. - (2016), s. 31-40
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27102948 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170830103951 $b ABA008
- 999 __
- $a ok $b bmc $g 1239731 $s 984963
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 302 $c - $d 31-40 $e 20160419 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
- LZP __
- $a Pubmed-20170720